drug_type
RELEVANT_DRUG
intervention_type
Drug (antibody–drug conjugate)
drug_description
A HER2-targeted antibody–drug conjugate composed of a humanized anti-HER2 monoclonal antibody linked via a cleavable linker to deruxtecan (DXd), a membrane-permeable topoisomerase I inhibitor. Binds HER2, is internalized, and releases DXd to inhibit topoisomerase I, causing DNA damage and a bystander effect; dosed 5.4 mg/kg IV every 3 weeks.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Trastuzumab Deruxtecan
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized anti-HER2 monoclonal antibody linked via a cleavable linker to deruxtecan (DXd), a membrane-permeable topoisomerase I inhibitor. After binding HER2 on tumor cells, the ADC is internalized and the linker is cleaved in lysosomes to release DXd, which inhibits topoisomerase I, inducing DNA damage and apoptosis; the membrane-permeable payload produces a bystander killing effect in adjacent cells.
drug_name
Trastuzumab deruxtecan (T-DXd)
nct_id_drug_ref
NCT05919212